Thirty Days Outcomes of Limb Salvage Surgery in Pediatric Patients Treated at a Tertiary Care Hospital

Muhammad Younus Khan Durrani1, Usman Ali1, Javeria Saeed1

  • 1Orthopaedic Surgery, Aga Khan University Hospital, Karachi, PAK.

Cureus
|December 30, 2024
PubMed

Insights

Limb salvage surgery for pediatric bone and soft tissue sarcomas shows a 26.3% complication rate within 30 days, with surgical site infections being most common. This highlights the need for improved infection control in low- and middle-income countries (LMICs).

Area of Science:

  • Pediatric Oncology
  • Orthopedic Surgery
  • Musculoskeletal Tumors

Background:

  • Limb salvage surgery is crucial for pediatric sarcoma cure but presents post-operative challenges.
  • Managing pediatric bone and soft tissue sarcomas requires specialized surgical approaches.
  • Concerns about post-operative complications in limb salvage surgery persist.

Purpose of the Study:

  • To evaluate the 30-day morbidity and mortality of limb salvage surgery in pediatric tumor patients.
  • To identify critical knowledge gaps in pediatric sarcoma management.
  • To contribute to enhancing the standard of care in low- and middle-income countries (LMICs).

Main Methods:

  • A prospective cohort study was conducted on pediatric patients (≤18 years) undergoing limb salvage surgery.
  • Data collected from May 2021 to October 2023 at a tertiary care hospital.
  • Nineteen cases met inclusion criteria for analysis.

Main Results:

  • The average patient age was 12.2 years; 63.2% had bone tumors, 36.8% soft tissue tumors.
  • Osteosarcoma (36.8%) and Ewing Sarcoma (31.57%) were most common.
  • 26.3% of patients experienced post-surgical complications within 30 days, including surgical site infections (21.05%) and flap necrosis (10.53%).

Conclusions:

  • Limb salvage surgery in pediatric musculoskeletal tumor patients has significant early complication rates, especially in LMICs.
  • Surgical site infections are a major concern, necessitating improved infection control measures.
  • Nearly one-quarter of patients faced adverse events within 30 days, underscoring ongoing challenges.